5月29日，康诺亚-B盘中上涨10.01%，报63.75港元/股，成交额1.12亿港元。
消息面上，申万宏源首次覆盖康诺亚-B并给予"买入"评级，目标价89.47港元，对应48%上涨空间。研报指出，核心产品司普奇拜单抗已有三项适应症获批并全部纳入国家医保目录，2025年药品销售收入达3.15亿元，同比增长776%。此外，公司NewCo合作伙伴被吉利德收购，康诺亚将获约2.5亿美元首付款。同日生物科技板块整体走强，信达生物涨12.83%，三生制药涨9.51%，康方生物涨8.24%，荣昌生物涨6.52%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.